Trimet - instructions for use, dose, side effects, contraindications

Sheath: hypromellose 1,204 mg, macrogol (polyethylene glycol 4000) 0.263 mg, titanium dioxide 0.066 mg, crimson dye (Ponso 4R) 0.745 mg, dye sunset sunset yellow 0.022 mg.

Description:Round biconvex tablets, covered with a shell, red.

Pharmacotherapeutic group:antihypoxic agent

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

C.01.E.B.15 Trimetazidine

Pharmacodynamics:Trimetazidine has an antianginal, antihypoxic effect. Directly affects the cardiomyocytes and neurons of the brain, optimizing their metabolism and function. The cytoprotective effect is caused by an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (increased aerobic glycolysis and fatty acid oxidation blockade). Supports contractility of the myocardium, prevents the decrease in intracellular content of ATP and phosphocreatinine. In conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemia zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase from cells and the severity of ischemic myocardial damage.

When the frequency of attacks of angina reduces (decreases nitrate consumption) after 2 weeks of treatment increases exercise capacity, reduced blood pressure drops. The hearing and results of vestibular samples in patients improve, dizziness and tinnitus decrease.

In vascular pathology, the eye restores the functional activity of the retina eyes.

Pharmacokinetics:

After taking the drug inside trimetazidine quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90%. Time to reach the maximum concentration in blood plasma - 2 hours (maximum concentration after a single dose of 20 mg of trimetazidine about 55 ng / ml). Easily penetrates through the histohematological barriers. The half-life (T1 / 2) is 4.5-5 hours. The connection with blood plasma proteins is 16%. It is excreted from the body by the kidneys (about 60% unchanged).

Indications:

Ischemic heart disease: prevention of angina attacks (in complex therapy);

Chorioretinal vascular disorders;

Vertigo of vascular origin;

Cohleo-vestibular disorders of ischemic nature (tinnitus, violation of hearing).

Contraindications:

Hypersensitivity to any component of the drug;

Renal failure (creatinine clearance below 15 ml / min);

Pronounced violations of the liver;

Pregnancy;

The period of breastfeeding;

Age to 18 years (effectiveness and safety not established).

Dosing and Administration:

Inside, with food.

The recommended dosing regimen is 2-3 tablets (40-60 mg) per day, in 2-3 doses. The course of treatment on the recommendation of a doctor.

Side effects:Allergic reactions (skin itching). Rarely from the gastrointestinal tract: gastralgia, nausea, vomiting; a headache, a strong palpitation.

Overdose:At present, no cases of drug overdose have been reported.

Interaction:

There is no information.

Special instructions:

The drug is not intended for relief of angina attacks.

Against the background of drug treatment in patients with coronary heart disease there is a significanta decrease in the daily requirement for nitrates.

Effect on the ability to drive transp. cf. and fur:

The use of the drug does not affect the ability to drive and perform work that requires a high rate of mental and physical reactions.

Form release / dosage:

The tablets covered with a cover, on 20 mg.

Packaging:

10 tablets in a strip of aluminum foil. 3 or 6 strips in a cardboard bundle with instructions for use.

Storage conditions:

Store at a temperature not exceeding 30 ° C.

Keep out of the reach of children.

Shelf life:3 years.

Do not use after the expiration date

Terms of leave from pharmacies:On prescription

Registration number:LSR-001309/08

Date of registration:29.02.2008

The owner of the registration certificate:TORRENT PHARMACEUTICALS LTD. TORRENT PHARMACEUTICALS LTD. India

Manufacturer: & nbsp

TORRENT PHARMACEUTICALS, Ltd. India

Representation: & nbspTORRENT PHARMACEUTICALS LTD. TORRENT PHARMACEUTICALS LTD. India

Information update date: & nbsp25.10.2015

Illustrated instructions

Instructions

Tremet (Trimet)